Literature DB >> 18566412

CD73 participates in cellular multiresistance program and protects against TRAIL-induced apoptosis.

Andrey Mikhailov1, Alice Sokolovskaya, Gennady G Yegutkin, Hanne Amdahl, Anne West, Hideo Yagita, Riitta Lahesmaa, Linda F Thompson, Sirpa Jalkanen, Dmitry Blokhin, John E Eriksson.   

Abstract

The molecular mechanisms underlying the multiresistant phenotype of leukemic and other cancer cells are incompletely understood. We used expression arrays to reveal differences in the gene expression profiles of an apoptosis-resistant T cell leukemia clone (A4) and normally apoptosis-sensitive parental Jurkat cells. CD73 (ecto-5'-nucleotidase) was the most up-regulated gene in the resistant A4 cell clone. A4 cells displayed CD73 surface expression and significant ecto-5'-nucleotidase activity. The role of CD73 was confirmed by transfection of wild-type CD73 into native Jurkat cells, which led to specific resistance against TRAIL-induced apoptosis, but not other types of apoptosis. The protective role of CD73 was further confirmed by small interfering RNA-mediated down-regulation of CD73, restoring TRAIL sensitivity. CD73-mediated resistance was independent of enzymatic activity of CD73, but was reliant on the anchoring of the protein to the membrane via GPI. We suggest that the inhibition of TRAIL signaling works through interaction of CD73 with death receptor 5, as CD73 and death receptor 5 could be coimmunoprecipitated and were shown to be colocalized in the plasma membrane by confocal microscopy. We propose that CD73 is a component of multiresistance machinery, the transcription of which is activated under selective pressure of the immune system.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566412      PMCID: PMC5584620          DOI: 10.4049/jimmunol.181.1.464

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Production and specificity of monoclonal antibodies against nodularin conjugated through N-methyldehydrobutyrine.

Authors:  A Mikhailov; A S Härmälä-Braskén; E Polosukhina; A Hanski; M Wahlsten; K Sivonen; J E Eriksson
Journal:  Toxicon       Date:  2001-10       Impact factor: 3.033

2.  MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors.

Authors:  S E Tran; T H Holmstrom; M Ahonen; V M Kahari; J E Eriksson
Journal:  J Biol Chem       Date:  2001-01-25       Impact factor: 5.157

3.  Ecto-5'-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin.

Authors:  P Ujházy; M Klobusická; O Babusíková; P Strausbauch; E Mihich; M J Ehrke
Journal:  Int J Cancer       Date:  1994-10-01       Impact factor: 7.396

Review 4.  A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance.

Authors:  Chuen-Pei Ng; Benjamin Bonavida
Journal:  Adv Cancer Res       Date:  2002       Impact factor: 6.242

5.  Extracellular ATP formation on vascular endothelial cells is mediated by ecto-nucleotide kinase activities via phosphotransfer reactions.

Authors:  G G Yegutkin; T Henttinen; S Jalkanen
Journal:  FASEB J       Date:  2001-01       Impact factor: 5.191

Review 6.  Novel mechanisms of drug resistance in leukemia.

Authors:  D D Ross
Journal:  Leukemia       Date:  2000-03       Impact factor: 11.528

7.  Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance.

Authors:  P Ujházy; E S Berleth; J M Pietkiewicz; H Kitano; J R Skaar; M J Ehrke; E Mihich
Journal:  Int J Cancer       Date:  1996-11-15       Impact factor: 7.396

8.  Impairment of tubuloglomerular feedback regulation of GFR in ecto-5'-nucleotidase/CD73-deficient mice.

Authors:  Hayo Castrop; Yuning Huang; Seiji Hashimoto; Diane Mizel; Pernille Hansen; Franziska Theilig; Sebastian Bachmann; Chuxia Deng; Josie Briggs; Jurgen Schnermann
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

9.  The evidence for two opposite, ATP-generating and ATP-consuming, extracellular pathways on endothelial and lymphoid cells.

Authors:  Gennady G Yegutkin; Tiina Henttinen; Sergei S Samburski; Jozef Spychala; Sirpa Jalkanen
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

10.  Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells.

Authors:  C Friesen; I Herr; P H Krammer; K M Debatin
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

View more
  27 in total

1.  CD73 represses pro-inflammatory responses in human endothelial cells.

Authors:  Jana Kg Grünewald; Anne J Ridley
Journal:  J Inflamm (Lond)       Date:  2010-02-05       Impact factor: 4.981

2.  Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.

Authors:  Huining Kang; I-Ming Chen; Carla S Wilson; Edward J Bedrick; Richard C Harvey; Susan R Atlas; Meenakshi Devidas; Charles G Mullighan; Xuefei Wang; Maurice Murphy; Kerem Ar; Walker Wharton; Michael J Borowitz; W Paul Bowman; Deepa Bhojwani; William L Carroll; Bruce M Camitta; Gregory H Reaman; Malcolm A Smith; James R Downing; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

Review 3.  Cell type- and tissue-specific functions of ecto-5'-nucleotidase (CD73).

Authors:  Marquet Minor; Karel P Alcedo; Rachel A Battaglia; Natasha T Snider
Journal:  Am J Physiol Cell Physiol       Date:  2019-08-28       Impact factor: 4.249

4.  Extracellular Adenosine Production by ecto-5'-Nucleotidase (CD73) Enhances Radiation-Induced Lung Fibrosis.

Authors:  Florian Wirsdörfer; Simone de Leve; Federica Cappuccini; Therese Eldh; Alina V Meyer; Eva Gau; Linda F Thompson; Ning-Yuan Chen; Harry Karmouty-Quintana; Ute Fischer; Michael Kasper; Diana Klein; Jerry W Ritchey; Michael R Blackburn; Astrid M Westendorf; Martin Stuschke; Verena Jendrossek
Journal:  Cancer Res       Date:  2016-02-26       Impact factor: 12.701

5.  CD73 Promotes Age-Dependent Accretion of Atherosclerosis.

Authors:  Nadia R Sutton; Diane Bouïs; Kris M Mann; Imran M Rashid; Alexandra L McCubbrey; Matt C Hyman; Daniel R Goldstein; Annie Mei; David J Pinsky
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-10-17       Impact factor: 8.311

Review 6.  Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.

Authors:  Sonali P Barwe; Anthony Quagliano; Anilkumar Gopalakrishnapillai
Journal:  Semin Oncol       Date:  2017-07-11       Impact factor: 4.929

7.  Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment.

Authors:  Sara Serra; Tiziana Vaisitti; Valentina Audrito; Cinzia Bologna; Roberta Buonincontri; Shih-Shih Chen; Francesca Arruga; Davide Brusa; Marta Coscia; Ozren Jaksic; Giorgio Inghirami; Davide Rossi; Richard R Furman; Simon C Robson; Gianluca Gaidano; Nicholas Chiorazzi; Silvia Deaglio
Journal:  Blood Adv       Date:  2016-11-22

8.  Upregulation of CD73 Confers Acquired Radioresistance and is Required for Maintaining Irradiation-selected Pancreatic Cancer Cells in a Mesenchymal State.

Authors:  Anna M Nguyen; Jianhong Zhou; Brihget Sicairos; Sangeetha Sonney; Yuchun Du
Journal:  Mol Cell Proteomics       Date:  2019-12-26       Impact factor: 5.911

9.  Antiproliferative and proapoptotic effects of a pyrrole containing arylthioindole in human Jurkat leukemia cell line and multidrug-resistant Jurkat/A4 cells.

Authors:  Alex A Philchenkov; Michael P Zavelevich; Volodymyr P Tryndyak; Ludmila M Kuiava; Dmitry Yu Blokhin; Koh Miura; Romano Silvestri; Igor P Pogribny
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

10.  Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.

Authors:  John Stagg; Upulie Divisekera; Nicole McLaughlin; Janelle Sharkey; Sandra Pommey; Delphine Denoyer; Karen M Dwyer; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.